METHOD FOR DETERMINATION OF ETIOLOGY OF FEVER OF UNKNOWN ORIGIN CANCER PATIENTS Russian patent published in 2018 - IPC G01N33/50 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, specifically to medical laboratory diagnostics in oncology, and allows differential diagnosis of fever of unknown origin. Method comprises collecting blood from the ulnar vein into a vacuum tube from the patient on the first day of fever or at the time of admission to hospital with a fever of unknown origin to obtain human serum or plasma, further, at the same time, method comprises quantitative determination of procalcitonin concentration a single blood sample, detection of the circulating mannan antigen Candida, detection of all antibodies of the class of immunoglobulins to the mannan antigen Candida. If the level of procalcitonin is equal to or greater than 0.5 ng/ml and less than 2 ng/ml, concentration of the mannan antigen Candida or 125 pg/ml, antibodies to the mannan antigen Candida greater than or equal to 10 AU/ml, invasive candidiasis is diagnosed. If the level of procalcitonin is equal to or greater than 2 ng/ml and less than 100 ng/ml, mannan antigen Candida concentration less than or equal to 62.5 pg/ml and with concentration of antibodies to mannan antigen Candida equal to 10 AU/ml and above or less than or equal to 5 AU/ml, severe bacterial infection, bacterial sepsis is diagnosed. If the level of procalcitonin is equal to or greater than 2 ng/ml and less than 100 ng/ml, concentration of mannan antigen Candida is greater than or equal to 125 pg/ml, in combination with the concentration of antibodies to the mannan antigen Candida greater than or equal to 10 AU/ml, a severe bacterial infection, bacterial sepsis in combination with invasive candidiasis is diagnosed. If the level of procalcitonin is equal to or greater than 0.5 ng/ml and less than 2 ng/ml, concentration of mannan antigen Candida is less than or equal to 62.5 pg/ml, concentration of antibodies to the mannan antigen Candida of 10 AU/ml and above or less than or equal to 5 AU/ml, non-infectious etiologic fever associated with the underlying oncological disease is diagnosed.

EFFECT: method allows differential diagnosis of fever of unknown origin in cancer patients.

1 cl, 4 ex